832-497-2220 [email protected]

4.30 Online Preliminary



Wellesley Pharmaceuticals, LLC was founded to ensure that the ability of Nocturol to reduce and sometimes eliminate Nocturia symptoms can be disseminated to help the hundreds of millions of people who can benefit from it. Nocturol’s ability to reduce bathroom visits is now supported by 9 issued US method-of-use patents that have been granted.  Patent protection around the world is underway. And patents have already having been granted in Australia, New Zealand, Russia, Singapore, South Africa, and Taiwan. The company also has a patent pending for a lower dose version of Nocturol that could be helpful for children who wet their beds.  About 3.2 million children ages 5-14 in the US wet their beds on a regular basis.  These children are likely to be treated successfully with Nocturol since most Nocturia sufferers and bedwetters share the same underlying cause, which is elevated prostaglandin levels.

Betalin Therapeutics

Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for millions of people with diabetes. Betalin Therapeutics licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development. Based on promising in vitro results and preliminary in vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA’s positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.

Breegi scientific

Breegi Scientific is developing the world’s first disposable incubator. Our infant incubator is the first multi-functional disposable Neonatal Intensive Care Incubator (NICI), a class II medical device that require a 510k application in the FDA and has a pending patents. With several innovative technologies, it is a practical user-friendly, efficient, low maintenance, inexpensive, incubator designed to significantly reduce neonatal mortality and morbidity in a challenging environment. Our disruptive platform innovation will provide the critical necessities for neonatal critical care such as heat, humidity, ventilation, phototherapy and containment for stationary and for transport cases. The NICI is designed to run on a 12 volts versatile convertible power source, allowing the device to be used anywhere operable on site or in transport vehicle as a portable incubator.


Nano-Textile developed a breakthrough, single-step nano-coating process, which is done via an IP protected sono-chemistry reactor. This allows us to embed nano-particles onto any kind of substrate, in an irreversible manner, unable to leave the substrate. The process, despite its innovation brilliancy, is a very cost effective and highly competitive process. Unlike other methods, Nano-textile’s uses cavitation to permanently permeate the textile with an environmentally friendly, cost effective solution. It has proven itself to be the only viable anti-bacterial solution in the world for hospitals due to the extremely long withstanding durability of the anti-bacterial properties and the limitless manufacturing potential, allowing us to implement our technology into any kind of fabric, either man-made or natural, with absolutely no damage or alteration to the fabrics’ original quality or color.


Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform. Our alphalex™ platform allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors. It enables intracellular, antigen-independent targeting of tumor cells with existing anti-cancer agents. The enhanced therapeutic index allows combinations of therapies with known synergistic efficacy at doses which were previously thought to be unreachable due to synergistic toxicity.


CRiL was formed in 2013 to develop digital respiratory health technology based on monitoring tidal breathing. We have developed a novel, low-cost LED-based sensor that measures respired CO2 highly accurately at the mouth. This sensor is contained within an N-Tidal device, which enables the patient to use normal tidal (relaxed) breathing to record their lung function. N-Tidal captures and analyses the CO2 measurements and transmits them securely to the cloud, providing access by clinicians and healthcare providers. CRiL has effectively “reinvented and reinterpreted” the capnometer. CRiL’s advanced prototype device has been used over 40,000 time is six clinical studies with more than 230 participants with COPD, asthma, congestive heart failure, breathing pattern disorders, pneumonia and Lou Gehrigs disease, as well as healthy people. N-Tidal will improve patient outcomes and reduce the cost of care.

Bio Noble Metals

Bio Noble Metals is developing new dental noble alloy composed of Pd (palladium), Ag (Silver) and In (indium). Our goal for the material is to be antibacterial and harmless to human bodies. Currently the market is urgent need of a new kind of alloy, as the gold alloy is getting more and more expensive. We researched the market need from 2005 to 2010, and applied our noble alloy bonded composite resin in dental clinics in Korea since 2010 and achieved success. This technology will contribute to dental care and metallurgy development. 

RS Research

RS Research is a next generation therapeutics company developing novel nanomedicines. We have developed a pioneering class of nanocarriers with which we currently have proprietary programs in various stages of preclinical development for treatment of cancer. Our nanocarrier platform is highly tunable with a plug & play approach, allowing speedy development of targeted nanomedicines with superior performance. Along with moving our very own candidates toward clinic, we provide preclinical services to industrial and academic partners. We have specific expertise in biosimilar characterization as well as in vivo experiment design.



Hao Chen

Venture Partner

GuoQian Venture Captial Investment (SuZhou) Co.,Ltd

Jinglei Zhang

Senior Consultant


Mingxi   Li


GT Healthcare Capital Partners

Hui Wang

Project Manager


Yonggang Li

Medical Implant Device National Engineering Lab Director


Haiping Chen